Home

Newsroom

Newsroom

Latest News

Press Releases

15

May
2023

Press Releases, Regulated

Celyad Oncology announces receipt of Nasdaq delisting notice

Download PDF

05

May
2023

Press Releases

Celyad Oncology reports first quarter 2023 financial results and recent business highlights

Download PDF

05

May
2023

Press Releases

Celyad Oncology announces intent to voluntarily delist American depository shares from Nasdaq

Download PDF

24

Apr
2023

Press Releases, Regulated

Celyad Oncology announces receipt of Nasdaq initial notification on ADS bid price

Download PDF

04

Apr
2023

Press Releases, Regulated

Celyad Oncology announces receipt of Nasdaq notice

Download PDF

24

Mar
2023

Corporate, Press Releases

Celyad Oncology appoints Georges Rawadi as its new CEO

Download PDF

23

Mar
2023

Financial Reports, Uncategorized

Celyad Oncology reports full year 2022 financial results and recent business highlights

Download PDF

17

Mar
2023

Corporate, Financial Reports

Celyad Oncology to announce full year 2022 financial results and host conference call

Download PDF

15

Mar
2023

Corporate, Press Releases, Regulated

Celyad Oncology announces non-cash impairment

Download PDF

01

Mar
2023

Letter to Shareholders, Press Releases, Regulated

Letter to Shareholders

Download PDF

09

Feb
2023

Clinical, Immuno-oncology, Press Releases

Celyad Oncology announces the publication of data from its Phase 1 THINK study of CYAD-01

Download PDF

03

Feb
2023

Corporate, Financial Reports, Press Releases

Celyad Oncology provides fourth quarter 2022 business update and 2023 outlook

Download PDF

21

Dec
2022

Clinical, Uncategorized

Celyad Oncology provides an update on its strategic business model, continuing to focus on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property

Download PDF

10

Nov
2022

Uncategorized

Celyad Oncology Announces Third Quarter 2022 Financial Results and Recent Business Highlights

Download PDF

12

Oct
2022

Uncategorized

Celyad Oncology Provides Strategic Update

Download PDF

20

Sep
2022

Uncategorized

Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction

Download PDF

05

Aug
2022

Uncategorized

Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights

Download PDF

01

Aug
2022

Uncategorized

Celyad Oncology Announces FDA Lifts Clinical Hold of CYAD-101-002 Phase 1b Trial

Download PDF

28

Jul
2022

Uncategorized

Celyad Oncology to Announce First Half 2022 Financial Results and Host Conference Call

Download PDF

24

Jun
2022

Uncategorized

Celyad Oncology Announces Leadership Updates

Download PDF

31

May
2022

Uncategorized

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Download PDF

17

May
2022

Uncategorized

Celyad Oncology to Present at the H.C. Wainwright Global Investment Conference

Download PDF

05

May
2022

Uncategorized

Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights

Download PDF

25

Mar
2022

Uncategorized

Letter to Shareholders – March 2022

Download PDF

24

Mar
2022

Uncategorized

Celyad Oncology Reports Full Year 2021 Financial Results and Recent Business Highlights

Download PDF

17

Mar
2022

Press Releases

Celyad Oncology to Announce Full Year 2021 Financial Results and Host Conference Call

Download PDF

02

Mar
2022

Uncategorized

Celyad Oncology Announces Clinical Hold of CYAD-101-002 Phase 1b Trial

Download PDF

28

Feb
2022

Uncategorized

Celyad Oncology Announces Voluntary Pause of CYAD-101-002 Phase 1b Trial

Download PDF

31

Jan
2022

Uncategorized

Celyad Oncology Announces February 2022 Conference Schedule

Download PDF

10

Jan
2022

Uncategorized

Celyad Oncology Provides Outlook for 2022

Download PDF

31

Dec
2021

Uncategorized

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Download PDF

22

Dec
2021

Uncategorized

Celyad Oncology Announces January 2022 Conference Schedule

Download PDF

17

Dec
2021

Uncategorized

Transparency notification received from Tolefi SA and related persons (Article 14 §1 of the Law of 2 May 2007)

Download PDF

16

Dec
2021

Uncategorized

Celyad Oncology Announces First Patient Dosed in KEYNOTE-B79 Phase 1b Trial

Download PDF

15

Dec
2021

Uncategorized

Transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)

Download PDF

13

Dec
2021

Uncategorized

Celyad Oncology Presents Updates on shRNA-Based CAR T Programs at the 63rd ASH Annual Meeting and Exposition

Download PDF

08

Dec
2021

Uncategorized

Celyad Oncology Announces Closing of $32.5 Million Private Placement with Fortress Investment Group Affiliate

Download PDF

03

Dec
2021

Uncategorized

Celyad Oncology Announces $32.5 Million Private Placement with Fortress Investment Group

Download PDF

12

Nov
2021

Uncategorized

Celyad Oncology Presents Preclinical Data on Allogeneic CAR T Therapy Program and Highlights KEYNOTE-B79 Clinical Trial Design at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Download PDF

10

Nov
2021

Uncategorized

Celyad Oncology Announces Third Quarter 2021 Financial Results and Recent Business Highlights

Download PDF

04

Nov
2021

Uncategorized

Celyad Oncology to Present Updates from Allogeneic and Autologous CAR T Programs at 63rd ASH Annual Meeting and Exposition

Download PDF

02

Nov
2021

Uncategorized

Celyad Oncology Announces November 2021 Conference Schedule

Download PDF

29

Oct
2021

Uncategorized

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Download PDF

01

Oct
2021

Uncategorized

Celyad Oncology to Present New Data on Allogeneic CAR T Therapy Program at the Society for Immunotherapy of Cancer Annual Meeting

Download PDF

01

Sep
2021

Uncategorized

Celyad Oncology announces September 2021 Conference Schedule

Download PDF

04

Aug
2021

Uncategorized

Celyad Oncology Reports First Half 2021 Financial Results and Recent Business Highlights

Download PDF

30

Jul
2021

Uncategorized

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Download PDF

29

Jul
2021

Uncategorized

Celyad Oncology to Announce First Half 2021 Financial Results and Host Conference Call

Download PDF

20

Jul
2021

Press Releases, Uncategorized

Celyad Oncology Presents Updates on Allogeneic CAR T Clinical Candidates and shRNA-based Preclinical Concepts at Research & Development Day

Download PDF

13

Jul
2021

Uncategorized

Celyad Oncology to Host Virtual Research & Development Webinar on July 20th

Download PDF

07

Jul
2021

Press Releases, Uncategorized

Celyad Oncology to Participate at the William Blair Biotech Focus Conference 2021

Download PDF

30

Jun
2021

Inside Information, Uncategorized

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Download PDF

11

Jun
2021

Uncategorized

Celyad Oncology Presents Preliminary Data from Phase 1 IMMUNICY-1 Trial of shRNA-based Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Association Virtual Congress

Download PDF

31

May
2021

Uncategorized

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Download PDF

26

May
2021

Press Releases, Uncategorized

Celyad Oncology Announces June 2021 Conference Schedule

Download PDF

19

May
2021

Press Releases, Uncategorized

Transparency Notification received from Victory Capital Management Inc. (Article 14 §1 of the Law of 2 May 2007)

Download PDF

12

May
2021

Press Releases

Celyad Oncology to Present Data from Phase 1 IMMUNICY-1 Trial of Non-Gene Edited Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Association Virtual Congress

Download PDF

06

May
2021

Uncategorized

Celyad Oncology Announces First Quarter 2021 Financial Results and Recent Business Highlights

Download PDF

05

May
2021

Uncategorized

Transparency notification received from Tolefi SA (Article 14 §1 of the Law of 2 May 2007)

Download PDF

04

May
2021

Uncategorized

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Download PDF

19

Apr
2021

Uncategorized

Celyad Oncology Appoints Dr. Charles Morris as Chief Medical Officer

Download PDF

01

Apr
2021

Uncategorized

Celyad Oncology Announces April 2021 Conference Schedule

Download PDF

31

Mar
2021

Uncategorized

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Download PDF

18

Mar
2021

Uncategorized

Celyad Oncology to Announce Full Year 2020 Financial Results and Host Conference Call

Download PDF

01

Mar
2021

Uncategorized

Celyad Oncology Announces March 2021 Conference Schedule

Download PDF

10

Feb
2021

Uncategorized

Letter to Shareholders – February 2021

Download PDF

02

Feb
2021

Uncategorized

Celyad Oncology Announces February 2021 Conference Schedule

Download PDF

18

Jan
2021

Uncategorized

Celyad Oncology Presents Data Update from Phase 1 alloSHRINK Trial for CYAD-101 in mCRC at ASCO-GI Symposium

Download PDF

11

Jan
2021

Uncategorized

Celyad Oncology Appoints Marina Udier, Ph.D., to Board of Directors

Download PDF

07

Jan
2021

Uncategorized

Celyad Oncology Announces Equity Purchase Agreement for up to $40 Million with Lincoln Park Capital

Download PDF

05

Jan
2021

Uncategorized

Celyad Oncology Announces January 2021 Conference Schedule

Download PDF

15

Dec
2020

Uncategorized

Celyad Oncology Successfully Doses First Patient in Expansion Cohort of the CYAD-101 Phase 1 alloSHRINK Trial for mCRC

Download PDF

07

Dec
2020

Uncategorized

Celyad Oncology Provides Updates on Allogeneic and Autologous CAR T Programs at 62nd ASH Annual Meeting and Exposition

Download PDF

04

Dec
2020

Uncategorized

Celyad Oncology Announces Dosing of First Patient in Phase 1 IMMUNICY-1 Trial of CYAD-211 for Multiple Myeloma

Download PDF

01

Dec
2020

Uncategorized

Celyad Oncology to Participate in a Fireside Chat at the JMP Securities Hematology Summit

Download PDF

10

Nov
2020

Uncategorized

Celyad Oncology Announces Third Quarter 2020 Financial Results and Recent Business Highlights

Download PDF

04

Nov
2020

Uncategorized

Celyad Oncology to Present Updates from Allogeneic and Autologous CAR T Programs at 62nd ASH Annual Meeting and Exposition

Download PDF

02

Nov
2020

Uncategorized

Celyad Oncology Announces November 2020 Investor Conference Schedule

Download PDF

29

Sep
2020

Uncategorized

Celyad Oncology Announces Clinical Trial Collaboration to Evaluate CYAD-101 with KEYTRUDA® (pembrolizumab) in Patients with Microsatellite Stable mCRC

Download PDF

23

Sep
2020

Uncategorized

Celyad Oncology to Participate in a Fireside Chat at the 7th Annual Jefferies Cell Therapy Summit

Download PDF

22

Sep
2020

Uncategorized

Celyad Oncology to Host Virtual Research & Development Webinar on September 29, 2020

14

Sep
2020

Uncategorized

Celyad Oncology Establishes At-the-Market Facility

Download PDF

26

Aug
2020

Uncategorized

Celyad Oncology Announces September 2020 Conference Schedule

Download PDF

06

Aug
2020

Uncategorized

Celyad Oncology Reports Half Year 2020 Financial Results and Second Quarter Business Highlights

Download PDF

03

Aug
2020

Uncategorized

Celyad Oncology to Announce First Half 2020 Financial Results and Host Conference Call

Download PDF

14

Jul
2020

Uncategorized

Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene Edited Allogeneic CAR T Therapy

Download PDF

.fl-heading-text